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Renin Inhibition in Hypertension
Alan H. Gradman, MD, Rishi Kad, MD
Pittsburgh, Pennsylvania
Fifty years ago, investigators identified renin inhibition as the preferred pharmacologic approach to blockade of
the renin–angiotensin system. Renin is a monospecific enzyme that catalyzes the rate-limiting step in the syn-
thesis of angiotensin II. Amplified enzymatic activity and additional physiological effects occur when renin and
pro-renin bind to the (pro)renin receptor. Until very recently, development of clinically effective renin inhibitors
remained elusive. Molecular modeling was used to develop aliskiren, a potent, low-molecular-weight, nonpep-
tide, direct renin inhibitor with sufficient bioavailability to produce sustained suppression of plasma renin activity
after oral administration. In patients with hypertension, aliskiren produces dose-dependent blood pressure (BP)
reduction and 24-h BP control up to a dose of approximately 300 mg once daily; at these doses, aliskiren shows
placebo-like tolerability. Its antihypertensive potency is approximately equivalent to that of angiotensin receptor
blockers, angiotensin-converting enzyme inhibitors, and diuretics. After abrupt withdrawal, persistent BP reduc-
tion and prolonged suppression of plasma renin activity is observed. When combined with diuretics, fully additive
BP reduction is seen. When given with an angiotensin receptor blocker, aliskiren produces significant additional
BP reduction indicative of complimentary pharmacology and more complete renin–angiotensin system block-
ade. Clinical trials are currently underway assessing the effects of aliskiren combined with an angiotensin
receptor blocker on intermediate markers of end organ damage, and long-term end point trials are planned. The
results of these studies will ultimately determine the place of renin inhibition and aliskiren in the treatment of
hypertension and related cardiovascular disorders. The effect of aliskiren on receptor-bound renin and pro-renin
is the subject of active investigation. (J Am Coll Cardiol 2008;51:519–28) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.027U
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bn 1957, Skeggs et al. (1) with rather remarkable foresight
ostulated 3 possible approaches to pharmacologic inhi-
ition of the renin–angiotensin system (RAS) (Fig. 1):
) inhibition of angiotensin-converting enzyme (ACE);
) direct interference with the action of angiotensin II
A II); and 3) inhibition of the circulating enzyme, renin.
Since renin is the initial and rate-limiting substance,” these
uthors observed, “the last approach would be the most
ikely to succeed.” In the intervening 50 years, ACE
nhibition and angiotensin II receptor type 1 (AT1) block-
de have indeed become integral components of cardiovas-
ular pharmacotherapy, compiling an impressive track
ecord in reducing blood pressure (BP) (2), changing the
atural history of heart failure (3–6) and proteinuric renal
isease (7–9), and conferring cardiovascular protection in a
ariety of clinical circumstances.
The development of clinically effective renin inhibitors
as, however, remained elusive because of difficulties in
dentifying suitable agents with the required combination of
igh affinity for renin’s active site and sufficient bioavailabil-
ty to permit chronic oral administration (10). The recent
rom the Division of Cardiovascular Diseases, The Western Pennsylvania Hospital,
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Manuscript received October 18, 2007; accepted October 24, 2007..S. Food and Drug Administration approval of the first
irect renin inhibitor, aliskiren, thus constitutes an impor-
ant milestone in the history of RAS blockade (11), making
t possible for the Skeggs et al. (1) theoretically preferred
pproach to receive widespread clinical application and
esting.
The Skeggs et al. (1) preference for renin inhibition was
ased on the fact that the reaction catalyzed by renin is the
rst and rate-limiting step in the synthesis of A II, which
as by then recognized as the primary effector hormone of
he RAS. The discovery of the (pro)renin receptor consti-
utes an additional reason to focus attention on renin
nhibition (12). When bound to the (pro)renin receptor, the
nzymatic activity of renin is amplified and renin exerts
hysiological effects that are entirely independent of A II
roduction. In addition, pro-renin, long thought to be
erely an inactive precursor of renin, becomes biologically
ctive when bound to this receptor. The expanding physi-
logical role ascribed to renin and pro-renin and the
ossibility that renin inhibitors could interfere with both
uggests that these agents could ultimately prove to have
ery different tissue effects compared with earlier RAS
lockers.
In this review we will discuss the structure and function ofenin and pro-renin, recent discoveries relevant to their
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able data regarding the effects of
the renin inhibitor aliskiren in the
treatment of hypertension and re-
lated cardiovascular disorders.
The Structure
and Function of Renin
Renin belongs to a family of en-
zymes referred to as aspartic pro-
teases, which also includes the en-
zymes pepsin, cathepsin, and
chymosin (13). Renin is a mono-
specific enzyme that displays re-
markable specificity for its only
known substrate, angiotensinogen.
Renin consists of 2 homolo-
gous lobes, with the active site
residing in the deep cleft located
between them (14,15) (Fig. 2).
The catalytic activity of the active
site is due to 2 aspartic acid
residues, 1 located in each lobe of
the renin molecule. A key com-
ponent of the active site is a
istinct subpocket (S3sp), which is specific to renin and
nique among the aspartate proteases (15). The active site
an accommodate 7 amino acid units of the substrate,
ngiotensinogen, and cleaves the Leu10-val11 peptide bond
ithin angiotensinogen to generate angiotensin I (A I).
Classically, our understanding of the function and impor-
ance of renin relates entirely to its role in the generation of A
I. The reaction catalyzed by renin is the rate-limiting step in
II formation. Neither A I nor A II can be synthesized at all
n the absence of renin (or, as discussed below, nonproteolyti-
ally activated pro-renin). In addition, the conversion of
Abbreviations
and Acronyms
A I/II  angiotensin I/II
ACE  angiotensin-
converting enzyme
BP  blood pressure
Cmax  maximum serum
concentration
dTGR  double transgenic
rats
HCTZ 
hydrochlorothiazide
LVH  left ventricular
hypertrophy
PAI  plasminogen
activator inhibitor
PRA  plasma renin
activity
PRC  plasma renin
concentration
RAS  renin–angiotensin
system
TGF  transforming growth
factor
Figure 1 The Renin–Angiotensin Cascade and the 3 Available A
to Pharmacologic Inhibition of Production or Action of
Direct renin inhibitors (DRI), angiotensin-converting enzyme inhibitors (ACEI), and angiotensinogen to A I is favored by a 5,000-fold concentra-
ion gradient, making it unlikely that substrate availability
ould limit A II production (10).
Renin is produced through activation of its enzymati-
ally inactive precursor, pro-renin. Pro-renin is synthe-
ized as a preprohormone, in that it contains a signal
eptide that leads the inactive molecule to the exterior of
he cell (16). Pro-renin concentration in human plasma is
pproximately 10-fold greater than the concentration of
enin (17), and the proportion of circulating pro-renin is
ncreased in patients with diabetes (18,19). The enzy-
atic inactivity of pro-renin is attributable to a 43-
mino-acid N-terminal pro-peptide that covers the active
ite and blocks access to angiotensinogen.
aches
iotensin II
nsin (AT) type 1 receptor blockers (ARB).
Figure 2 X-Ray Crystallographic Representation of Aliskiren
in the Binding Complex With Human Renin
Renin molecule consists of 2 homologous lobes with the active site located in
the cleft between the 2 lobes. Aliskiren occupies a specific subpocket in the
cleft and blocks the enzymatic function of renin.ppro
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February 5, 2008:519–28 Renin InhibitionPro-renin may be rendered enzymatically active in 2
ays, proteolytic and nonproteolytic activation. Proteolytic
ctivation occurs via the actual removal of the pro-peptide
hain. Most proteolytic activation of pro-renin occurs in the
uxtaglomerular cells of the kidney leading to the production
f active renin (20). Nonproteolytic activation is a 2-step
rocess that allows pro-renin to acquire enzymatic activity
ithout removal of the pro-segment. This process involves
nfolding of the pro-peptide chain away from the enzymatic
left followed by an additional conformational change (21).
onproteolytic activation can be induced in vitro by expo-
ure to cold and/or low pH (22,23) and, as discussed below,
hrough binding to the (pro)renin receptor.
he (pro)renin receptor. In 2002, Nguyen et al. (12)
iscovered a high-affinity binding site for renin in cultured
uman mesangial cells. This site was subsequently cloned
nd is believed to represent the principal (pro)renin recep-
or. The term (pro)renin receptor is used to indicate that
his receptor binds to both renin and pro-renin; in fact,
inding to pro-renin occurs with somewhat greater affinity
han to renin itself (24). The structure of the receptor
onsists of a 350-amino-acid protein with a single trans-
embrane domain. To date, (pro)renin receptors have been
ocalized to vascular smooth muscle cells; to human heart,
idney, and brain; to mesangial cells; and to cells in the
istal and collecting tubules of the renal parenchyma (12).
When renin binds to the (pro)renin receptor, its enzy-
atic activity is increased by 4- to 5-fold, accelerating the
roduction of A I on the cell surface where it lies in close
roximity both to tissue-bound ACE and to the AT1
eceptor. The binding of pro-renin results in nonproteolytic
ctivation because of the conformational changes described
bove. This process allows pro-renin to assume full enzy-
atic activity and contribute to A I production. There is
xperimental evidence to suggest that the sequestration of
irculating (pro)renin and its subsequent nonproteolytic
ctivation may, in fact, be responsible for a large fraction of
he A I production that occurs at the tissue level (12,25).
When bound to the (pro)renin receptor, both renin and
ro-renin exert physiological effects which are entirely inde-
endent of A II (25–27). In various experimental models, renin
nd/or pro-renin have been shown to activate intracellular
ignaling pathways (p42/p44 and p38 MAP kinase), induce
NA synthesis, and stimulate the release of transforming
rowth factor (TGF)- and plasminogen activator inhibitor
PAI)-1 (27–29) (Fig. 3). In one study, Huang et al. (29)
howed that renin induced a dose-dependent increase in
esangial cell TGF- despite the presence of a renin inhibitor
RO 42-5892), an angiotensin receptor blocker (losartan), or
n ACE inhibitor (enalapril). Thus, this effect occurred with-
ut production of A II or stimulation of the AT1 receptor.
evelopment of Renin Inhibitors
he first-generation renin inhibitors were peptide analogues
f the pro-segment of renin or substrate analogues of the l-terminal amino-acid sequence of the renin substrate,
ngiotensinogen. Substitution of the dipeptide moiety at the
leavage site (the so-called scissile bond) resulted in selective
enin inhibitors with an inhibitory potency in the micromo-
ar range. Subsequently, compounds were developed in
hich the peptides at the scissile bond were replaced by
oncleavable analogues with resultant potency in the nano-
olar range (10,13,30,31,34).
Several of these peptide-like analogues were tested in
nimals and humans for their mechanistic and hemody-
amic effects. In studies using sodium-depleted marmosets,
he renin inhibitor, CGP 29 287, produced dose-dependent
nhibition of plasma renin activity (PRA) and lowered BP
uring intravenous infusion (32). (PRA is determined using
radioimmunoassay that measures the capacity of plasma to
enerate A I, reflecting renin’s enzymatic activity and not
he mass of circulating renin. The latter is referred to as the
lasma renin concentration [PRC].) Both remikiren and
ankiren were shown to reduce PRA and increase PRC after
ral administration indicating renin inhibition (30,33–35).
hen remikiren was administered to patients with hyper-
ension, however, no statistically significant BP reduction
as seen after 8 days of oral dosing (35,36).
As a group, the peptidomimetic renin inhibitors showed
igh in vitro and in vivo potency. However, their large
olecular size and lipophilicity resulted in poor intestinal
bsorption and considerable first-pass hepatic metabo-
Figure 3 Direct Intracellular Effects
Mediated Via (Pro)Renin Receptors
Renin and pro-renin directly activate intracellular signaling pathways, including
mitogen-activated protein kinases (MAPK), leading to generation of transform-
ing growth factor-beta (TGF-), plasminogen activator inhibitor-1 (PAI-1), and
heat shock protein 27 (Hsp27). Activation is independent of angiotensin II.
Reprinted with permission from Nguyen and Danser (27).ism, significantly limiting oral bioavailability (34). In
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Renin Inhibition February 5, 2008:519–28ddition, all of these agents had short elimination half
ives and high costs of synthesis and production. These
actors precluded their successful development as antihy-
ertensive agents (10).
liskiren
he development of aliskiren was approached in a logical,
nalytical fashion and represents a significant breakthrough in
edicinal chemistry. Renin is a protein that is soluble in water
nd amenable to X-ray crystallographic analysis (15). This
rovided the opportunity to analyze X-ray diffraction data for
rystals of renin bound to renin inhibitors. Molecular modeling
as then used to design a novel, low-molecular-weight, non-
eptide renin inhibitor (37). The extended peptide-like back-
one that characterized earlier peptidomimetic renin inhibitors
as eliminated. The addition of various alkylether aromatic
ide chains promoted interaction with the S3sp subpocket of
he active site and dramatically enhanced aliskiren’s affinity for
enin and its selectivity over other aspartic peptidases. Addi-
ional molecular remodeling, by replacement and substitution
f side chains, resulted in a less lipophilic compound with a
onger duration of action after oral dosing. Later, Drs. Alice
uxley (for whom aliskiren is named), Peter Herold, and
thers using retrosynthesis analysis were successful in simpli-
ying the synthetic process and reducing the high cost of
anufacture (38).
Aliskiren is an extremely potent competitive inhibitor of
enin with an IC50 (concentration inhibiting 50% of activ-
ty) of 0.6 nmol/l (37). It has high specificity for primate
enin, and shows a 10,000-fold lower affinity for related
spartic peptidases. This high specificity for renin makes it
nlikely to produce adverse effects through interaction with
ther enzymes. In comparison with earlier renin inhibitors,
liskiren has favorable physiochemical properties with high
queous solubility and lower lipophilicity, rendering it more
esistant to degradation. This leads to improved bioavail-
bility (approximately 2.6%) after oral administration.
reclinical studies: pharmacodynamic. Species differ-
nces in the amino acid sequence of renin and angiotensino-
en render human renin inhibitors weak as inhibitors of
enin isoforms in nonprimate species (13,39). Thus,
liskiren inhibits human, marmoset, and rat plasma renin
ith IC50 values of 0.6, 2, and 80 nmol/l, and can be studied
n marmosets (which are primates) but not in the commonly
sed rat models of hypertension. In marmosets that were
odium-depleted to activate the RAS, aliskiren at doses of 1
nd 3 mg/kg produced complete inhibition of PRA for 6
nd 24 h, respectively (40). Single oral doses lowered BP in
dose-dependent fashion. In the same animal model,
liskiren was more effective in reducing BP compared with
he peptidomimetic renin inhibitors, remikiren and
ankiren. Aliskiren was as effective in reducing BP as were
omparable doses of valsartan and benazepril.
reclinical studies: end organ protection. The specificity
f aliskiren for primate renin precludes the use of most (nimal models in which end organ effects of antihyperten-
ive agents are commonly evaluated. The development of
ouble transgenic rats (dTGR), which express the human
enes for both renin and angiotensinogen, has provided a
uitable animal model in which to investigate the tissue
rotective effects of renin inhibitors (41,42).
Pilz et al. (43) compared aliskiren and valsartan in
reventing target organ damage in dTGR. Matched
-week-old dTGR received either no treatment, low-dose
r high-dose aliskiren, or low-dose or high-dose valsartan.
ntreated dTGR showed severe hypertension, albuminuria,
nd increased serum creatinine by week 7, and 100%
ortality rate by week 9. In contrast, high-dose valsartan
nd both doses of aliskiren lowered BP, reduced albumin-
ria and creatinine levels, and resulted in 100% survival at
eek 9. Treatment with aliskiren and high-dose valsartan
lso reduced left ventricular hypertrophy (LVH); the mag-
itude of this effect was somewhat greater with high-dose
liskiren.
In other renal protection studies using the double trans-
enic rat model, aliskiren reduced renal inflammation and
brosis as well as albuminuria (44). In dTGR rats with
iabetic nephropathy, aliskiren reduced albuminuria and
ther markers of renal damage, including gene expression of
GF- and collagens III and IV (45). When aliskiren was
ompared with ACE inhibitors or angiotensin receptor
lockers (ARBs), the renal protective effects were approxi-
ately equal (43,45).
linical pharmacology. In healthy male subjects over a
ide range of doses (40 to 1,800 mg), the plasma concen-
ration of aliskiren peaks at 2 to 4 h after oral administra-
ion. The terminal half is 23 to 36 h, making the drug
uitable for once-daily administration (46). The maximum
erum concentration (Cmax), Cmax at steady state, and area
nder the curve all increase proportionally after doses 80
g. Administration of aliskiren with food results in lower
ean Cmax and area under the curve values than are
btained in the fasting state, although the drug was given
ithout regard to meals in clinical trials. After a single
ntravenous infusion of 20 mg in healthy males, the plasma
learance of aliskiren was approximately 9 l/h, and the
epatic extraction ratio was approximately 10% with only
inor involvement of the first-pass metabolism (46). The
olume of distribution was approximately 135 l. In humans,
liskiren is 47% to 51% protein bound (47).
Aliskiren seems to have low potential for significant drug
nteractions. Co-administration of aliskiren did not signif-
cantly affect the pharmacokinetics of lovastatin, digoxin,
alsartan, amlodipine, metformin, celecoxib, atenolol, atorva-
tatin, ramipril, hydrochlorothiazide (HCTZ), or warfarin
48–51). When aliskiren was co-administered with furo-
emide, the area under the curve and Cmax of furosemide were
educed by about 30% and 50%, respectively (52).
ffects on the RAS. In a crossover study in normotensive
olunteers receiving a low-sodium diet, Nussberger et al.
53) evaluated the effects of 4 oral doses of aliskiren (40, 80,
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February 5, 2008:519–28 Renin Inhibition60, and 640 mg) compared with placebo and the ACE
nhibitor enalapril (20 mg) on components of the RAS.
fter single oral doses and 8 days of repeated once-daily
osing, aliskiren reduced PRA in a dose-dependent manner.
ompared with placebo, the highest doses of aliskiren
educed A II levels by a maximum of 89% and 75% on days
and 8, respectively. At doses of aliskiren 80 mg/day,
here was a 40% to 50% decrease in both plasma and urinary
ldosterone levels. Higher doses of aliskiren enhanced
atriuresis. Although enalapril reduced A II levels acutely to
comparable degree as aliskiren, its administration was
ssociated with a 15-fold increase in PRA. Both aliskiren
nd enalapril increased PRC.
Azizi et al. (54) examined the mechanistic aspects of dual
AS blockade after single oral doses of aliskiren and the AT1
eceptor blocker valsartan. In a crossover study, placebo,
liskiren (300 mg), valsartan (160 mg), and a low-dose com-
ination of the 2 drugs (aliskiren 150 mg  valsartan 80 mg)
ere given to 12 sodium-depleted normotensive men. As
onotherapy, aliskiren decreased PRA. Valsartan increased
RA as well as circulating levels of A I and A II. In the
ombination arm, PRA, A I, and A II levels were approxi-
ately equal to placebo. Thus, addition of aliskiren eliminated
he compensatory increase in PRA and its downstream prod-
cts that occurred after acute ARB administration.
liskiren in Hypertension
liskiren has been extensively evaluated, as monotherapy
nd in combination with other agents, in clinical trials
nvolving more than 11,000 adult patients with hyperten-
ion. In several trials PRA and PRC were measured,
roviding an opportunity to observe the effect of chronic
Figure 4 Antihypertensive Effects of Aliskiren Compared With P
Results of the pooled analysis in 8,481 patients treated with aliskiren 150 and 30
represent least-squares mean reduction  standard error of the mean; values in t
SBP  systolic blood pressure. Data from Dahlöf et al. (63).ral dosing on components of the RAS. yomparison with placebo. Eight placebo-controlled trials
ave assessed the antihypertensive effects of aliskiren mono-
herapy (55–62). Short-term treatment (4 to 8 weeks) with
nce-daily aliskiren at doses 75 mg/day consistently pro-
uced significant BP reduction compared with placebo. A
ose-response relationship was documented up to 300
g/day; little or no additional BP reduction was observed
ith a higher dose (600 mg). When given for 8 weeks, three
oses of aliskiren (150, 300, and 600 mg/day) reduced PRA
y 70% to 73% from baseline without a measurable dose-
ependent effect on this parameter. Increases in PRC were
ose-related in patients receiving 150 mg (128%), 300 mg
180%), and 600 mg (386%).
Most of the antihypertensive effects of aliskiren were
chieved during the first 2 weeks, and near-maximum BP
eduction occurred by week 4. As measured by 24-h
mbulatory BP monitoring, aliskiren significantly reduced
ean ambulatory systolic and diastolic BP over 24 h. The
ntihypertensive effect was sustained throughout the dosing
nterval with trough-to-peak ratios of 64% for the 150 mg
ose and 98% for the 300 mg dose as reported in one study.
A pooled analysis reported by Dahlöf et al. (63) included
,481 patients who participated in double-blind trials and
eceived treatment with aliskiren monotherapy or placebo
or 8 to 12 weeks (Fig. 4). Once-daily aliskiren, 150 and 300
g, produced reductions in mean trough sitting diastolic
P of 10.1 and 11.8 mm Hg, respectively, compared with
.2 mm Hg for placebo (p  0.0001). Trough systolic BP
as lowered by 12.5 and 15.2 mm Hg, compared with 5.9
m Hg for placebo (p  0.0001). There was no
tatistical difference in the magnitude of BP reduction in
en and women or in patients younger or older than 65
bo
compared with placebo. ***p  0.0001 versus placebo. Values under the bars
ows represent placebo-subtracted reductions. DBP  diastolic blood pressure;lace
0 mg
he arrears.
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Renin Inhibition February 5, 2008:519–28omparison with other antihypertensive agents. Alis-
iren has been compared with commonly used antihyper-
ensive agents, including HCTZ, ramipril, and several
ngiotensin receptor blockers. In general, the efficacy of
liskiren was similar to other antihypertensive drugs. Eight
eeks of treatment with aliskiren at doses of 150 and 300
g/day resulted in BP reduction comparable to that of
tandard therapy with low-dose HCTZ (12.5 mg/day, 25
g/day). Monotherapy with HCTZ activated the RAS.
he PRA increased by 44.7% at a dose of 12.5 mg/day and
1.9% with 25 mg/day; corresponding increases in PRC
ere 26.1% and 108.4%, respectively (56).
Two trials have compared the BP-lowering effects of
liskiren with that of the ACE inhibitor ramipril. In
ypertensive diabetic patients, aliskiren (300 mg) was
qually effective in lowering mean sitting diastolic BP (the
rimary efficacy variable) compared with ramipril (10 mg)
64). A significantly greater reduction in sitting systolic BP
as seen in aliskiren-treated patients. Similar results were
btained in a longer term (6 months) comparison of
liskiren and ramipril in nondiabetic hypertensive patients
65). Ramipril also produced RAS activation. In one study,
amipril 10 mg increased both PRA (110.6%) and PRC
67.9%).
Multiple studies have evaluated the efficacy and safety of
liskiren in comparison with various ARBs (losartan, irbe-
artan, valsartan). In a 4-week study that included ambula-
ory BP monitoring, there was no statistical difference
etween the change in daytime systolic BP with 100 mg/day
osartan and 300 mg aliskiren (66). In another study, the
ntihypertensive efficacy of aliskiren 150 mg was found to
e similar to that of irbesartan 150 mg/day, which at this
ose increased both PRA (116.3%) and PRC
107.0%) (55). Aliskiren was compared directly with
alsartan as part of an 8-week study in which both drugs
ere forced-titrated to their maximum U.S. Food and
rug Administration-approved dosage (aliskiren 300 mg,
alsartan 320 mg); reductions in systolic BP and diastolic
P were almost identical (13.0/9.0 mm Hg, 12.8/9.7 mm
g, p  NS) (61).
afety. In a pooled analysis of data including 2,316 patients
ho received aliskiren monotherapy, the tolerability profile
f aliskiren was similar to that of placebo or ARBs at doses
p to 300 mg daily (67). At the 600-mg dose, an increased
ncidence of diarrhea (9.5%) was observed in comparison
ith placebo (1.2%). The total number of reported ad-
erse events and the rate of discontinuation because of
dverse events were similar to those for placebo. Serious
dverse events occurred in 11 patients (0.5%) who received
liskiren compared with 5 patients (0.6%) who received
lacebo.
ersistence of effect after discontinuation. The effects
ccurring after abrupt withdrawal of aliskiren have been
nvestigated in several controlled studies. Rebound hyper-
ension has not been reported. On the contrary, persistence
f BP-lowering effects has been consistently documented 368–70). In one study, patients who had received 11 months
f aliskiren monotherapy were randomized to continued
liskiren or placebo during a 4-week double-blind with-
rawal phase. Patients receiving placebo had a gradual
ncrease in BP during the withdrawal period. The BP in the
lacebo group did not return to pre-treatment values,
owever, and PRA remained 50% below baseline levels,
ndicating that the renin inhibition provided by aliskiren
xtends well beyond the plasma half-life of the drug (70)
Fig. 5). This prolonged suppression of PRA might be
xplained by animal studies showing the localization and
etention of aliskiren in the kidneys of dTGR for up to 3
eeks after its discontinuation (71).
ombination therapy. Most patients with hypertension
equire multiple drugs, and the safety and efficacy of
liskiren has been studied in combination with thiazide
iuretics, calcium channel blockers, ACE inhibitors, and
RBs (56,60,61,64,72). For reasons discussed later, consid-
rable emphasis has been placed on the evaluation of
liskiren in combination with other blockers of the RAS.
Because of their complimentary pharmacologic actions,
iuretics are natural combination partners with drugs such
s aliskiren that block the RAS. In a large factorial design
tudy, 2776 patients with stage I and II hypertension
eceived placebo, aliskiren (75, 150, or 300 mg), HCTZ
6.25, 12.5, or 25 mg), or various combinations of aliskiren
HCTZ over an 8-week period (56). The BP reduction
ith combinations of aliskiren and HCTZ seemed to be
ully additive (i.e., the BP-reducing effect observed with
ombinations was approximately equal to the sum of BP
eduction obtained with each component) less the placebo
esponse. At the highest combination dose (aliskiren 300
gHCTZ 25 mg), an average BP reduction of 21.2/14.3
m Hg was seen. In obese hypertensive subjects, aliskiren
Figure 5 Persistent PRA
Suppression After Aliskiren Withdrawal
Measurements of plasma renin activity (PRA) after withdrawal of aliskiren in
patients on long-term aliskiren therapy showed a persistent 50% reduction in
PRA during a 4-week double-blind withdrawal phase. †End point is defined as
the end of the 1-month withdrawal period or the last visit carried forward. Data
from Pool et al. (70).00 mg/HCTZ 25 mg was equipotent compared with
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February 5, 2008:519–28 Renin Inhibitionrbesartan 300 mg/HCTZ 25 mg indicating that the com-
ination of a renin inhibitor and a diuretic is as effective as
ommonly used diuretic/ARB combinations (60). Combi-
ation with aliskiren blocked the increases in PRA seen
ith HCTZ monotherapy while PRC levels increased
arkedly. Administration of aliskiren/HCTZ 150/12.5 mg
educed PRA (49.6%) and increased PRC (305%).
One study has assessed the efficacy and tolerability of
liskiren combined with a calcium channel blocker (72).
atients showing an inadequate response to amlodipine 5
g/day were randomized to either continued therapy with
mlodipine 5 mg, up-titration to amlodipine 10 mg, or the
ddition of aliskiren 150 mg to amlodipine 5 mg. Up-
itration of amlodipine or addition of aliskiren resulted in
ignificantly greater BP reduction than continuation of
mlodipine 5 mg/day, with no difference between the
ow-dose combination and high-dose amlodipine. The
0-mg amlodipine dose was associated with a higher inci-
ence of treatment-related peripheral edema (a dose-
ependent side effect of calcium channel blockers) com-
ared with the low-dose combination (11.2% vs. 2.1%).
mportant unanswered questions include the potency of
igher dose combinations and whether aliskiren, like ACE
nhibitors, will be found to decrease the rate of treatment-
mergent edema seen with high doses of amlodipine and
ther calcium channel blockers.
ual RAS blockade. The effects of dual RAS blockade
ith aliskiren and the ACE inhibitor ramipril were studied
n 837 patients with diabetes and hypertension (64). The
oses used in this study were the most commonly used dose
f ramipril (10 mg), the maximum recommended dose of
liskiren (300 mg), and the combination of these doses
aliskiren/ramipril 300/10 mg). The BP was reduced by
6.6/12.8 mm Hg with combination therapy, which was
tatistically greater than the BP reduction seen with
liskiren (14.7/11.3 mm Hg) or ramipril (12.0/10.7 mm
g) alone. Combination with the renin inhibitor blocked
he increases in PRA seen with ACE inhibitor mono-
herapy while PRC levels increased significantly.
The clinical effectiveness and safety of a high-dose
ombination of aliskiren and the ARB valsartan was tested
n 1,797 patients with a mean baseline BP 154/100 mm Hg
61). Patients were randomly assigned to receive placebo,
liskiren, valsartan, or the combination of aliskiren/
alsartan. Dosage in the active treatment arms was titrated
o the maximum recommended doses of each agent
aliskiren 300 mg, valsartan 320 mg); the combination dose
as aliskiren/valsartan 300/320 mg.
The high-dose combination reduced BP by a mean of
7.2/12.2 mm Hg, significantly greater than was observed
ith either component (aliskiren 13.0/9.0 mm Hg, valsartan
2.8/9.7 mm Hg). The PRA increased with valsartan
160%), decreased with aliskiren (73%), and was also
uppressed by the combination (44%). The PRC in-
reased with all active treatments; the increase in the
ombination therapy arm (912%) was statistically greater than that seen with aliskiren (468%) or valsartan (138%)
lone.
The high-dose combination of aliskiren and valsartan was
ell tolerated. There was an increased incidence of hyper-
alemia (K 5.5 mmol/l) in patients receiving the com-
ination compared with those receiving monotherapy. In 13
f 18 patients with this finding, potassium returned to the
ormal range at study end without dosage adjustment (61).
enin Inhibition: Perspective
enin inhibitors are a new class of agents, and there are as
et no clinical data regarding the ability of aliskiren to
revent clinical end points or reduce end organ damage over
nd above the presumed effects of BP reduction per se.
lthough there are supportive data from animal studies, it is
lso unknown whether aliskiren will prove to be superior,
qual, or inferior to ACE inhibitors or ARBs in terms of
nd organ protection. These are the key outstanding ques-
ions, the answers to which will ultimately determine the
lace of renin inhibition and aliskiren in the treatment of
ypertension and related cardiovascular disorders.
There are reasons to speculate that renin inhibition might
rove to be a superior strategy for blocking the RAS
ompared with existing drugs. These relate to effects on A
I generation, as well as to possible influences on the
ctivities of renin and pro-renin when bound to (pro)renin
eceptors. Aliskiren is a potent inhibitor of renin, and its
ioavailability is sufficient to produce sustained suppression
f PRA and BP reduction after chronic oral dosing. This
uppression is present whether the drug is given alone or in
ombination and persists after drug discontinuation. It is
ogical to assume that PRA suppression also leads to
ownstream suppression of A II formation.
The long-term effects of aliskiren on circulating A II
evels have, however, not been reported. In a recent article,
ealey and Laragh (73) raised the question of whether the
arked increases in PRC levels seen with aliskiren might be
ufficient to overwhelm the renin inhibition produced by the
rug. These investigators hypothesize that the inability of
liskiren to reduce BP by more than is achieved with ACE
nhibitors and ARBs suggests that an ACE–escape-like
henomenon may be operative. The observation that the
ercentage inhibition of PRA remains relatively constant
espite escalating aliskiren doses also suggests that signifi-
ant A II generation may continue despite renin inhibition.
ata regarding circulating A II levels in hypertensive
atients receiving aliskiren would be useful in quantifying
he degree of RAS suppression actually achieved with
hronic dosing.
The discovery of the (pro)renin receptor and ongoing
lucidation of its functions are rapidly changing our con-
eptual understanding of the RAS. Available data point to
n expanded role for renin and a pathogenetic role for
ro-renin in the genesis of human disease. The observation
hat pro-renin becomes biologically active when bound to
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Renin Inhibition February 5, 2008:519–28he (pro)renin receptor is of particular interest in view of
ata linking pro-renin with the development of microvas-
ular disease in diabetic patients (18,19). If renin inhibitors
lock these newly recognized actions of renin and pro-renin,
his might well constitute a therapeutic advantage over
CE inhibitors and ARBs.
The effects of aliskiren on events occurring at the (pro)renin
eceptor remain largely unknown, however. In a recent article,
guyen (74) succinctly summarized the important outstanding
ssues (Fig. 6). The first question is whether or not aliskiren
nhibits the enzymatic activity of renin and pro-renin when
hey are bound to the (pro)renin receptor. The answer to
his question will be particularly important in understanding
liskiren’s mechanism of action.
Another fundamental question is whether renin inhibi-
ors alter the non–A II-mediated activation of intracellular
ignaling pathways produced by receptor-bound renin and
ro-renin. The direct receptor-mediated effects described to
ate are similar to classic tissue responses to AT1 receptor
timulation, and are known to contribute to the develop-
ent of cellular hypertrophy and fibrosis. Available evidence
uggests that aliskiren does not inhibit these actions (75),
ut further investigation is clearly needed to clarify this
mportant issue. In addition, because some renin inhibitors
re known to drastically modify the structure of renin, future
enin inhibitors may have different effects than aliskiren on
he binding of renin to its receptor.
The ability of renin and pro-renin to produce potentially
dverse effects independent of A II has raised concern that
ncreases in PRC seen after aliskiren administration could
ave undesirable consequences. This seems unlikely because
ost available antihypertensive agents, including diuretics,
alcium channel blockers, ACE inhibitors, and ARBs, also
ncrease circulating renin levels. If increased renin levels
Figure 6 Possible Effects of Renin Inhibitors
on Receptor-Bound Renin and Pro-Renin
Potential sites of inhibition of the enzymatic activity and direct intracellular
effects of receptor-bound renin and pro-renin. ERK1/2  extracellular signal-
regulated kinase 1/2; PAI-1  plasminogen activator inhibitor-1; TGF-  trans-
forming growth factor-beta. Reprinted with permission from Nguyen (74).aere deleterious, it is doubtful that these drugs would be as
ffective as they are in reducing long-term cardiovascular
nd points. Nevertheless, the PRC levels reported after
dministration of aliskiren—particularly when combined
ith other drugs—are significantly higher than have been
een with other antihypertensive regimens, and negative
onsequences cannot be categorically excluded.
In this context, it should be noted that there are meth-
dological problems regarding the accuracy of PRC mea-
urements made in the presence of renin inhibitors, includ-
ng aliskiren. Renin levels are measured by direct
mmunoassay using a radiolabeled antibody specific for
enin. In some circumstances, renin inhibitors are known to
e capable of nonproteolytically activating pro-renin via
onformational changes described earlier. Depending on the
ncubating conditions, this activated pro-renin can be de-
ected by direct immunoassays as renin, leading to overes-
imation of renin concentration (76). Therefore, the mag-
itude of PRC increases reported in recent trials with
liskiren requires verification.
The results of the aliskiren/valsartan combination on BP
upport the concept that renin inhibitors and ARBs work by
harmacologic mechanisms that are distinct and compli-
entary. Like many hormonal systems, the RAS is self-
egulating and controlled by negative feedback inhibition.
timulation of the AT1 receptor by A II suppresses renin
elease. By blocking the interaction of A II with its receptor,
RBs interfere with this negative feedback loop and stim-
late renin production. When valsartan is given as mono-
herapy, PRA increases, whereas when it is combined with
liskiren, PRA is reduced (61). If compensatory RAS
ctivation truly limits the effectiveness of AT1 receptor
lockade, it is a reasonable hypothesis that simultaneous
dministration of a renin inhibitor will produce more
omplete RAS suppression and better end organ protection
ompared with an ARB alone.
A combination strategy is being utilized in studies exam-
ning the effects of aliskiren on intermediate markers of
nd organ damage. In the recently presented ALOFT
ALiskiren Observation oF Heart Failure Treatment) study,
he addition of aliskiren, 150 mg/day, to standard therapy
or heart failure (which included either an ACE inhibitor or
RB, if tolerated) resulted in significant reductions in the
NP levels in patients receiving aliskiren compared with
tandard therapy alone (77). In the ongoing AVOID
Aliskiren in eValuation of prOteinuria in Diabetes) study,
liskiren 300 mg/day or placebo is being added to back-
round therapy with losartan 100 mg/day in hypertensive
iabetic patients with proteinuria. The purpose of the study
s to determine whether combination treatment reduces
lbuminuria more effectively than losartan given at doses
hat have been shown to be renal protective.
In the ALLAY (Aliskiren in Left Ventricular Assessment
f Hypertrophy) trial, overweight patients with hyperten-
ion and LVH are receiving blinded treatment with
liskiren (300 mg), losartan (100 mg), or the combination
(
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February 5, 2008:519–28 Renin Inhibitionaliskiren/losartan 300/100 mg). The primary end point is
eft ventricular mass assessed by magnetic resonance imag-
ng to determine whether the addition of a renin inhibitor
ncreases the magnitude of LVH regression compared with
hat achievable with an ARB alone. Data from this study
lso should be helpful in excluding a negative effect related
o excessive stimulation of (pro)renin receptors by elevated
RC levels because the intracellular changes initiated by
pro)renin receptor stimulation promote hypertrophy and
brosis, which are central to LVH development.
In summary, 50 years after it was postulated to be the
referred approach to RAS blockade, an orally effective
enin inhibitor has been introduced into clinical medicine.
any of the basic questions that must be answered when
valuating any new antihypertensive agent have been ad-
ressed. Aliskiren produces dose-dependent BP reduction
nd placebo-like tolerability up to the plateau in the
ose-response curve that occurs at approximately 300 mg/
ay. Its antihypertensive potency is equivalent to those of
RBs, ACE inhibitors, and diuretics. Critical questions
egarding the effectiveness of aliskiren in blocking the effects
f renin/pro-renin at the site of the (pro)renin receptor
emain to be answered. Clinical trials planned or in progress
ill address issues related to end organ protection and
eduction in long-term cardiovascular end points.
eprint requests and correspondence: Dr. Alan H. Gradman,
he Western Pennsylvania Hospital, 4800 Friendship Avenue,
orth Tower, Suite 3411, Pittsburgh, Pennsylvania 15224.
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